By Ethan Covey
Intramuscular antiretroviral therapy (ART) that can be given every four or eight weeks appears to be as effective as current oral treatments and has the potential to increase adherence, according to a recent international study.
“The two-drug combination of all-injectable, long-acting cabotegravir [ViiV Healthcare] plus rilpivirine [Edurant, Janssen], every four weeks or every eight weeks was as effective as daily three-drug oral therapy at maintaining HIV-1 viral suppression